中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
THE CHINESE JOURNAL OF CLINICAL PHARMACOLOGY
2014年
12期
1083-1085
,共3页
紫杉醇脂质体%吉西他滨%顺铂%非小细胞肺癌
紫杉醇脂質體%吉西他濱%順鉑%非小細胞肺癌
자삼순지질체%길서타빈%순박%비소세포폐암
liposomal paclitaxel%gemcitabine%cisplatin%non-small cell lung cancer
目的:评价紫杉醇脂质体或吉西他滨联合顺铂治疗晚期非小细胞肺癌( NSCLC)的疗效与安全性。方法68例晚期NSCLC患者随机均分为紫杉醇脂质体联合顺铂(LP)组(n=34)和吉西他滨联合顺铂(GP)组(n=34)。 LP组:静脉滴注紫杉醇脂质体135 mg· m-2,静脉滴注顺铂75 mg· m-2;GP组:第1,8天静脉滴注吉西他滨1000 mg· m-2,第1天静脉滴注顺铂75 mg· m-2。21 d为1个疗程,比较2组患者的临床疗效、生存期和不良反应。结果2组患者的肺癌原发灶客观缓解率和疾病控制率差别无统计学意义( P>0.05);LP组转移区域淋巴结的客观缓解率(44.1%)、中位生存期(17.0个月)和1年生存率明显高于GP组( P<0.05)。 LP组的胃肠道反应和血小板减少的发生率明显低于GP组( P<0.05);2组患者在肝肾功能损伤、粒细胞减少、贫血、过敏和脱发等差异无统计学意义( P>0.05)。结论紫杉醇脂质体联合顺铂方案可延长NSCLC患者中位生存时间,不良反应较轻。
目的:評價紫杉醇脂質體或吉西他濱聯閤順鉑治療晚期非小細胞肺癌( NSCLC)的療效與安全性。方法68例晚期NSCLC患者隨機均分為紫杉醇脂質體聯閤順鉑(LP)組(n=34)和吉西他濱聯閤順鉑(GP)組(n=34)。 LP組:靜脈滴註紫杉醇脂質體135 mg· m-2,靜脈滴註順鉑75 mg· m-2;GP組:第1,8天靜脈滴註吉西他濱1000 mg· m-2,第1天靜脈滴註順鉑75 mg· m-2。21 d為1箇療程,比較2組患者的臨床療效、生存期和不良反應。結果2組患者的肺癌原髮竈客觀緩解率和疾病控製率差彆無統計學意義( P>0.05);LP組轉移區域淋巴結的客觀緩解率(44.1%)、中位生存期(17.0箇月)和1年生存率明顯高于GP組( P<0.05)。 LP組的胃腸道反應和血小闆減少的髮生率明顯低于GP組( P<0.05);2組患者在肝腎功能損傷、粒細胞減少、貧血、過敏和脫髮等差異無統計學意義( P>0.05)。結論紫杉醇脂質體聯閤順鉑方案可延長NSCLC患者中位生存時間,不良反應較輕。
목적:평개자삼순지질체혹길서타빈연합순박치료만기비소세포폐암( NSCLC)적료효여안전성。방법68례만기NSCLC환자수궤균분위자삼순지질체연합순박(LP)조(n=34)화길서타빈연합순박(GP)조(n=34)。 LP조:정맥적주자삼순지질체135 mg· m-2,정맥적주순박75 mg· m-2;GP조:제1,8천정맥적주길서타빈1000 mg· m-2,제1천정맥적주순박75 mg· m-2。21 d위1개료정,비교2조환자적림상료효、생존기화불량반응。결과2조환자적폐암원발조객관완해솔화질병공제솔차별무통계학의의( P>0.05);LP조전이구역림파결적객관완해솔(44.1%)、중위생존기(17.0개월)화1년생존솔명현고우GP조( P<0.05)。 LP조적위장도반응화혈소판감소적발생솔명현저우GP조( P<0.05);2조환자재간신공능손상、립세포감소、빈혈、과민화탈발등차이무통계학의의( P>0.05)。결론자삼순지질체연합순박방안가연장NSCLC환자중위생존시간,불량반응교경。
Objective To evaluate the clinical efficacy and safety of liposomal paclitaxel/gemcitabine combined with cisplatin on advanced non-small cell lung cancer ( NSCLC ).Methods Sixty -eight cases with advanced NSCLC were recruited and randomly divided into LP group ( n=34 ) and GP group ( n=34 ).Patients in the LP group were given liposomal paclitaxel 135 mg· m-2 and cisplatin 75 mg· m-2 on the first day by intravenous infusion.Patients in the GP group were given gemci-tabine 1000 mg · m-2 on the first and eighth day and cisplatin 75 mg· m-2 on the first day by intravenous infusion.The treatment lasted for twenty-one days.The clinical efficacy , survival time and adverse re-actions were compared between the two groups.Results There were no statistical difference in the aspects of objective response rate and disease control rate in the primary lesions of the two groups ( P>0.05 ).But the objective response rate of lymph node in LP group (44.1%) , the medi-an survival time (17 months), and one-year survival rate in LP group were higher than those in the GP group ( P<0.05 ).The incidences of gastrointestinal reactions and thrombocytopenia in LP group were much lower than those in GP group ( P<0.05 ) .The adverse reactions of liver and kidney dysfunction , neutropenia , anemia , allergies and hair loss in two groups had no statistical differences ( P<0.05 ).Conclusion Liposomal paclitaxel combined with csiplatin can improve the median survival period of advanced non -small cell lung cancer patients and decrease adverse reactions.